{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:50:31Z","timestamp":1777287031551,"version":"3.51.4"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurogenetics"],"DOI":"10.1007\/s10048-025-00858-z","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:57:41Z","timestamp":1761893861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CRISPR-based gene therapy for huntington\u2019s disease: current advances and future prospects"],"prefix":"10.1007","volume":"26","author":[{"given":"Amna","family":"Zaheer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha Mohamed","family":"AboQuella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al-Hassan Soliman","family":"Wadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hager Adel","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danisha","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaliza","family":"Panjwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shree","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Ijlal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"858_CR1","doi-asserted-by":"publisher","unstructured":"Prevalence and Incidence of Huntington\u2019s Disease An Updated Systematic Review and Meta-Analysis - Medina \u2013\u20092022 - Movement Disorders - Wiley Online Library. Accessed: Aug. 19, 2025. [Online]. Available: https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/mds.29228","DOI":"10.1002\/mds.29228"},{"key":"858_CR2","doi-asserted-by":"publisher","unstructured":"Kay C, Hayden MR, Leavitt BR (2017) Chapter 3 - Epidemiology of Huntington disease, in Handbook of Clinical Neurology, vol. 144, A. S. Feigin and K. E. Anderson, Eds., in Huntington Disease, vol. 144., Elsevier, pp. 31\u201346. https:\/\/doi.org\/10.1016\/B978-0-12-801893-4.00003-1","DOI":"10.1016\/B978-0-12-801893-4.00003-1"},{"issue":"3","key":"858_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JHD-200404","volume":"9","author":"M Anil","year":"2020","unstructured":"Anil M, Mason SL, Barker RA (2020) The clinical features and progression of late-onset versus younger-onset in an adult cohort of huntington\u2019s disease patients. J Huntingtons Dis 9(3):275\u2013282. https:\/\/doi.org\/10.3233\/JHD-200404","journal-title":"J Huntingtons Dis"},{"issue":"5","key":"858_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.12502","volume":"4","author":"FB Rodrigues","year":"2017","unstructured":"Rodrigues FB et al (2017) Survival, mortality, causes and places of death in a European Huntington\u2019s disease prospective cohort. Mov Disord Clin Pract 4(5):737\u2013742. https:\/\/doi.org\/10.1002\/mdc3.12502","journal-title":"Mov Disord Clin Pract"},{"key":"858_CR5","first-page":"65","volume":"5","author":"J Schulte","year":"2011","unstructured":"Schulte J, Littleton JT (2011) The biological function of the Huntingtin protein and its relevance to Huntington\u2019s disease pathology. Curr Trends Neurol 5:65\u201378","journal-title":"Curr Trends Neurol"},{"issue":"16","key":"858_CR6","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1093\/hmg\/ddp242","volume":"18","author":"M Swami","year":"2009","unstructured":"Swami M et al (2009) Somatic expansion of the Huntington\u2019s disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet 18(16):3039\u20133047. https:\/\/doi.org\/10.1093\/hmg\/ddp242","journal-title":"Hum Mol Genet"},{"key":"858_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"A-C Bachoud-L\u00e9vi","year":"2019","unstructured":"Bachoud-L\u00e9vi A-C et al (2019) International guidelines for the treatment of Huntington\u2019s disease. Front Neurol 10:710. https:\/\/doi.org\/10.3389\/fneur.2019.00710","journal-title":"Front Neurol"},{"issue":"5","key":"858_CR8","first-page":"852","volume":"54","author":"SE Andrew","year":"1994","unstructured":"Andrew SE et al (1994) Huntington disease without CAG expansion: phenocopies or errors in assignment? Am J Hum Genet 54(5):852\u2013863","journal-title":"Am J Hum Genet"},{"key":"858_CR9","doi-asserted-by":"publisher","unstructured":"Pengo M, Squitieri F (2024) Repeats BCAG: The multifaceted role of genetics in huntington disease. Genes 15(6):807. https:\/\/doi.org\/10.3390\/genes15060807","DOI":"10.3390\/genes15060807"},{"issue":"12","key":"858_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci 6(12):919\u2013930. https:\/\/doi.org\/10.1038\/nrn1806","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"858_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ncb3101","volume":"17","author":"Y-N Rui","year":"2015","unstructured":"Rui Y-N et al (2015) Huntingtin functions as a scaffold for selective macroautophagy. Nat Cell Biol 17(3):262\u2013275. https:\/\/doi.org\/10.1038\/ncb3101","journal-title":"Nat Cell Biol"},{"key":"858_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1175598","volume":"15","author":"J Yang","year":"2023","unstructured":"Yang J, Zhang C (2023) Targeting the autophagy-lysosomal pathway in huntington disease: a pharmacological perspective. Front Aging Neurosci 15:1175598. https:\/\/doi.org\/10.3389\/fnagi.2023.1175598","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"858_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jnc.14853","volume":"151","author":"EE Wanker","year":"2019","unstructured":"Wanker EE, Ast A, Schindler F, Trepte P, Schnoegl S (2019) The pathobiology of perturbed mutant huntingtin protein-protein interactions in Huntington\u2019s disease. J Neurochem 151(4):507\u2013519. https:\/\/doi.org\/10.1111\/jnc.14853","journal-title":"J Neurochem"},{"issue":"3","key":"858_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/sj.cdd.4402261","volume":"15","author":"T Zuchner","year":"2008","unstructured":"Zuchner T, Brundin P (2008) Mutant huntingtin can paradoxically protect neurons from death. Cell Death Differ 15(3):435\u2013442. https:\/\/doi.org\/10.1038\/sj.cdd.4402261","journal-title":"Cell Death Differ"},{"issue":"8","key":"858_CR15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.2174\/1871527316666170613084801","volume":"16","author":"GD Colpo","year":"2017","unstructured":"Colpo GD, Rocha NP, Stimming EF, Teixeira AL (2017) Immunomodulatory strategies for huntington\u2019s disease treatment. CNS Neurol Disord Drug Targets 16(8):936\u2013944. https:\/\/doi.org\/10.2174\/1871527316666170613084801","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"858_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.15283\/ijsc.2009.2.2.102","volume":"2","author":"W Im","year":"2009","unstructured":"Im W, Lee S-T, Chu K, Kim M, Roh J-K (2009) Stem cells transplantation and Huntington\u2019s disease. Int J Stem Cells 2(2):102\u2013108. https:\/\/doi.org\/10.15283\/ijsc.2009.2.2.102","journal-title":"Int J Stem Cells"},{"issue":"2","key":"858_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JHD-170245","volume":"6","author":"AM Travessa","year":"2017","unstructured":"Travessa AM, Rodrigues FB, Mestre TA, Ferreira JJ (2017) Fifteen years of clinical trials in Huntington\u2019s disease: a very low clinical drug development success rate. J Huntingt Dis 6(2):157\u2013163. https:\/\/doi.org\/10.3233\/JHD-170245","journal-title":"J Huntingt Dis"},{"key":"858_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep23549","volume":"6","author":"Y Miyaoka","year":"2016","unstructured":"Miyaoka Y et al (2016) Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing. Sci Rep 6:23549. https:\/\/doi.org\/10.1038\/srep23549","journal-title":"Sci Rep"},{"issue":"3","key":"858_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H et al (2021) CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med 384(3):252\u2013260. https:\/\/doi.org\/10.1056\/NEJMoa2031054","journal-title":"N Engl J Med"},{"issue":"1","key":"858_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31286-4","volume":"13","author":"Y Schary","year":"2023","unstructured":"Schary Y et al (2023) CRISPR-Cas9 editing of TLR4 to improve the outcome of cardiac cell therapy. Sci Rep 13(1):4481. https:\/\/doi.org\/10.1038\/s41598-023-31286-4","journal-title":"Sci Rep"},{"issue":"1","key":"858_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45078-3","volume":"13","author":"D Sastre","year":"2023","unstructured":"Sastre D et al (2023) Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces MtDNA damage and oxidative stress levels in human stem cell model of parkinson\u2019s disease. Sci Rep 13(1):17796. https:\/\/doi.org\/10.1038\/s41598-023-45078-3","journal-title":"Sci Rep"},{"key":"858_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.omtn.2022.03.022","volume":"28","author":"E Konstantinidis","year":"2022","unstructured":"Konstantinidis E et al (2022) CRISPR-Cas9 treatment partially restores amyloid-\u03b2 42\/40 in human fibroblasts with the Alzheimer\u2019s disease PSEN 1 M146L mutation. Mol Ther 28:450\u2013461. https:\/\/doi.org\/10.1016\/j.omtn.2022.03.022","journal-title":"Mol Ther"},{"key":"858_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.932936","volume":"10","author":"L Xiaoshuai","year":"2022","unstructured":"Xiaoshuai L, Qiushi W, Rui W (2022) Advantages of CRISPR-Cas9 combined organoid model in the study of congenital nervous system malformations. Front Bioeng Biotechnol 10:932936. https:\/\/doi.org\/10.3389\/fbioe.2022.932936","journal-title":"Front Bioeng Biotechnol"},{"key":"858_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","volume":"17","author":"FK Ekman","year":"2019","unstructured":"Ekman FK, Ojala DS, Adil MM, Lopez PA, Schaffer DV, Gaj T (2019) CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington\u2019s disease mouse model. Mol Ther 17:829\u2013839. https:\/\/doi.org\/10.1016\/j.omtn.2019.07.009","journal-title":"Mol Ther"},{"issue":"5","key":"858_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41551-023-01007-3","volume":"7","author":"S Yan","year":"2023","unstructured":"Yan S et al (2023) Cas9-mediated replacement of expanded CAG repeats in a pig model of huntington\u2019s disease. Nat Biomed Eng 7(5):629\u2013646. https:\/\/doi.org\/10.1038\/s41551-023-01007-3","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"858_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2016.10.014","volume":"25","author":"EL van Agtmaal","year":"2017","unstructured":"van Agtmaal EL et al (2017) CRISPR\/Cas9-induced (CTG\u22c5CAG)n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing. Mol Ther 25(1):24\u201343. https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.014","journal-title":"Mol Ther"},{"issue":"24","key":"858_CR27","doi-asserted-by":"publisher","first-page":"9607","DOI":"10.1073\/pnas.0902420106","volume":"106","author":"D Mittelman","year":"2009","unstructured":"Mittelman D et al (2009) Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc Natl Acad Sci U S A 106(24):9607\u20139612. https:\/\/doi.org\/10.1073\/pnas.0902420106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"858_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13272","volume":"7","author":"C Cinesi","year":"2016","unstructured":"Cinesi C, Aeschbach L, Yang B, Dion V (2016) Contracting CAG\/CTG repeats using the CRISPR-Cas9 nickase. Nat Commun 7:13272. https:\/\/doi.org\/10.1038\/ncomms13272","journal-title":"Nat Commun"},{"key":"858_CR29","unstructured":"Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice - PubMed. Accessed: Aug. 20, 2025. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/31253581\/"},{"key":"858_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.omtn.2021.11.024","volume":"27","author":"B Cardinali","year":"2022","unstructured":"Cardinali B et al (2022) Time-controlled and muscle-specific CRISPR\/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene. Mol Ther Nucleic Acids 27:184\u2013199. https:\/\/doi.org\/10.1016\/j.omtn.2021.11.024","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"858_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","volume":"25","author":"AM Monteys","year":"2017","unstructured":"Monteys AM, Ebanks SA, Keiser MS, Davidson BL (2017) CRISPR\/Cas9 editing of the mutant Huntingtin allele in vitro and in vivo. Mol Ther 25(1):12\u201323. https:\/\/doi.org\/10.1016\/j.ymthe.2016.11.010","journal-title":"Mol Ther"},{"key":"858_CR32","doi-asserted-by":"publisher","unstructured":"Murillo A et al (2024) Cas9 nickase-mediated contraction of CAG\/CTG repeats at multiple disease loci.\u00a0bioRxiv. https:\/\/doi.org\/10.1101\/2024.02.19.580669","DOI":"10.1101\/2024.02.19.580669"},{"issue":"1","key":"858_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02304-w","volume":"4","author":"S Oura","year":"2021","unstructured":"Oura S et al (2021) Precise CAG repeat contraction in a huntington\u2019s disease mouse model is enabled by gene editing with SpCas9-NG. Commun Biol 4(1):771. https:\/\/doi.org\/10.1038\/s42003-021-02304-w","journal-title":"Commun Biol"},{"issue":"1","key":"858_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-024-02079-6","volume":"22","author":"P Sledzinski","year":"2024","unstructured":"Sledzinski P, Nowaczyk M, Smielowska MI, Olejniczak M (2024) CRISPR\/Cas9-induced double-strand breaks in the Huntingtin locus lead to CAG repeat contraction through DNA end resection and homology-mediated repair. BMC Biol 22(1):282. https:\/\/doi.org\/10.1186\/s12915-024-02079-6","journal-title":"BMC Biol"},{"issue":"6096","key":"858_CR35","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816\u2013821. https:\/\/doi.org\/10.1126\/science.1225829","journal-title":"Science"},{"issue":"6121","key":"858_CR36","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L et al (2013) Multiplex genome engineering using CRISPR\/Cas systems. Science 339(6121):819\u2013823. https:\/\/doi.org\/10.1126\/science.1231143","journal-title":"Science"},{"key":"858_CR37","unstructured":"DNA targeting specificity of RNA-guided Cas9 nucleases | Nature Biotechnology. Accessed: Aug. 20 (2025) [Online]. Available: https:\/\/www.nature.com\/articles\/nbt.2647"},{"key":"858_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00075","volume":"12","author":"M Dabrowska","year":"2018","unstructured":"Dabrowska M, Juzwa W, Krzyzosiak WJ, Olejniczak M (2018) Precise excision of the CAG tract from the Huntingtin gene by Cas9 nickases. Front Neurosci 12:75. https:\/\/doi.org\/10.3389\/fnins.2018.00075","journal-title":"Front Neurosci"},{"key":"858_CR39","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1093\/hmg\/ddw286","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin JW et al (2016) Permanent inactivation of huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet 25:4566\u20134576. https:\/\/doi.org\/10.1093\/hmg\/ddw286","journal-title":"Hum Mol Genet"},{"issue":"7","key":"858_CR40","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1172\/JCI92087","volume":"127","author":"S Yang","year":"2017","unstructured":"Yang S et al (2017) CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of huntington\u2019s disease. J Clin Invest 127(7):2719\u20132724. https:\/\/doi.org\/10.1172\/JCI92087","journal-title":"J Clin Invest"},{"issue":"47","key":"858_CR41","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.1021\/bi101208k","volume":"49","author":"KT Gagnon","year":"2010","unstructured":"Gagnon KT et al (2010) Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49(47):10166\u201310178. https:\/\/doi.org\/10.1021\/bi101208k","journal-title":"Biochemistry"},{"key":"858_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nbd.2017.12.015","volume":"104","author":"P Dietrich","year":"2017","unstructured":"Dietrich P, Shanmugasundaram J, Shuyu N, Khoshnan HA (2017) Inhibition of wild-type Huntingtin exon 1 aggregation by mutant Huntingtin. Neurobiol Dis 104:15\u201324. https:\/\/doi.org\/10.1016\/j.nbd.2017.12.015","journal-title":"Neurobiol Dis"},{"issue":"10","key":"858_CR43","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/hmg\/ddi147","volume":"14","author":"JM Van Raamsdonk","year":"2005","unstructured":"Van Raamsdonk JM et al (2005) Loss of wild-type Huntingtin influences motor dysfunction and survival in the YAC128 mouse model of huntington disease. Hum Mol Genet 14(10):1379\u20131392. https:\/\/doi.org\/10.1093\/hmg\/ddi147","journal-title":"Hum Mol Genet"},{"key":"858_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104637","volume":"134","author":"RL McAdam","year":"2020","unstructured":"McAdam RL (2020) Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the httQ140\/Q140 mouse model of Huntington\u2019s disease. Neurobiol Dis 134:104637. https:\/\/doi.org\/10.1016\/j.nbd.2019.104637","journal-title":"Neurobiol Dis"},{"issue":"11","key":"858_CR45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/nmeth.1261","volume":"5","author":"W Liu","year":"2008","unstructured":"Liu W et al (2008) Linking SNPs to CAG repeat length in Huntington\u2019s disease patients. Nat Methods 5(11):951\u2013953. https:\/\/doi.org\/10.1038\/nmeth.1261","journal-title":"Nat Methods"},{"key":"858_CR46","doi-asserted-by":"publisher","unstructured":"Shin J-W, Kim AW, Kim SH, Kim JH (2017) Permanent inactivation of huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. PLoS Genet 13(7):e1006846. https:\/\/doi.org\/10.1371\/journal.pgen.1006846","DOI":"10.1371\/journal.pgen.1006846"},{"issue":"11","key":"858_CR47","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/ejhg.2017.125","volume":"25","author":"MJ Chao","year":"2017","unstructured":"Chao MJ et al (2017) Haplotype-based stratification of huntington\u2019s disease. Eur J Hum Genet 25(11):1202\u20131209. https:\/\/doi.org\/10.1038\/ejhg.2017.125","journal-title":"Eur J Hum Genet"},{"issue":"21","key":"858_CR48","doi-asserted-by":"publisher","first-page":"E9313","DOI":"10.1073\/pnas.1524575113","volume":"114","author":"FL Monteys","year":"2017","unstructured":"Monteys FL, Ebanks DA, Keiser KA, Davidson DR (2017) CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 114(21):E9313\u2013E9322. https:\/\/doi.org\/10.1073\/pnas.1524575113","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"7536","key":"858_CR49","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2015","unstructured":"Konermann S et al (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517(7536):583\u2013588. https:\/\/doi.org\/10.1038\/nature14136","journal-title":"Nature"},{"key":"858_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00794-w","author":"Y Lin","year":"2025","unstructured":"Lin Y et al (2025) RNA-targeting CRISPR\/CasRx system relieves disease symptoms in huntington\u2019s disease models. Mol Neurodegener. https:\/\/doi.org\/10.1186\/s13024-024-00794-w","journal-title":"Mol Neurodegener"},{"issue":"6","key":"858_CR51","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-e","volume":"72","author":"Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72(6):971\u2013983. https:\/\/doi.org\/10.1016\/0092-8674(93)90585-e","journal-title":"Cell"},{"issue":"5","key":"858_CR52","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.tins.2023.02.005","volume":"46","author":"W Duan","year":"2023","unstructured":"Duan W, Urani E, Mattson MP (2023) The potential of gene editing for Huntington\u2019s disease. Trends Neurosci 46(5):365\u2013376. https:\/\/doi.org\/10.1016\/j.tins.2023.02.005","journal-title":"Trends Neurosci"},{"issue":"10","key":"858_CR53","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1093\/brain\/awab190","volume":"144","author":"H Liu","year":"2021","unstructured":"Liu H et al (2021) Huntingtin silencing delays onset and slows progression of Huntington\u2019s disease: a biomarker study. Brain 144(10):3101\u20133113. https:\/\/doi.org\/10.1093\/brain\/awab190","journal-title":"Brain"},{"issue":"8","key":"858_CR54","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1007\/s12035-023-03347-2","volume":"60","author":"A Pirone","year":"2023","unstructured":"Pirone A et al (2023) Proteomic profiling reveals specific molecular hallmarks of the pig claustrum. Mol Neurobiol 60(8):4336\u20134358. https:\/\/doi.org\/10.1007\/s12035-023-03347-2","journal-title":"Mol Neurobiol"},{"issue":"11","key":"858_CR55","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8(11):2281\u20132308. https:\/\/doi.org\/10.1038\/nprot.2013.143","journal-title":"Nat Protoc"},{"key":"858_CR56","doi-asserted-by":"publisher","unstructured":"Yan S et al (May 2018) A Huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington\u2019s disease. Cell 173(4):989\u20131002. https:\/\/doi.org\/10.1016\/j.cell.2018.03.005. .e13","DOI":"10.1016\/j.cell.2018.03.005"},{"issue":"12","key":"858_CR57","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/procel\/pwad014","volume":"14","author":"G Yang","year":"2023","unstructured":"Yang G, Lu B (2023) Hunting out the repeat expansion in Huntington\u2019s pigs. Protein Cell 14(12):871\u2013873. https:\/\/doi.org\/10.1093\/procel\/pwad014","journal-title":"Protein Cell"},{"issue":"5","key":"858_CR58","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cell.2006.07.025","volume":"126","author":"LA Banaszynski","year":"2006","unstructured":"Banaszynski LA, Chen L, Maynard-Smith LA, Ooi AGL, Wandless TJ (2006) A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126(5):995\u20131004. https:\/\/doi.org\/10.1016\/j.cell.2006.07.025","journal-title":"Cell"},{"issue":"4","key":"858_CR59","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ (2020) Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat Nanotechnol 15(4):313\u2013320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6","journal-title":"Nat Nanotechnol"},{"key":"858_CR60","doi-asserted-by":"publisher","unstructured":"Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR\/Cas9 - Cheng \u2013\u20092014 - FEBS Letters - Wiley Online Library. Accessed: Aug. 21, 2025. [Online]. Available: https:\/\/febs.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1016\/j.febslet.2014.09.008","DOI":"10.1016\/j.febslet.2014.09.008"},{"issue":"7","key":"858_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500454","volume":"1","author":"X Han","year":"2015","unstructured":"Han X et al (2015) Crispr-Cas9 delivery to hard-to-transfect cells via membrane deformation. Sci Adv 1(7):e1500454. https:\/\/doi.org\/10.1126\/sciadv.1500454","journal-title":"Sci Adv"},{"issue":"7320","key":"858_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature09523","volume":"468","author":"JE Garneau","year":"2010","unstructured":"Garneau JE et al (2010) The CRISPR\/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468(7320):67\u201371. https:\/\/doi.org\/10.1038\/nature09523","journal-title":"Nature"},{"issue":"2","key":"858_CR63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1534\/genetics.115.176594","volume":"200","author":"W Qin","year":"2015","unstructured":"Qin W et al (2015) Efficient CRISPR\/Cas9-mediated genome editing in mice by zygote electroporation of nuclease. Genetics 200(2):423\u2013430. https:\/\/doi.org\/10.1534\/genetics.115.176594","journal-title":"Genetics"},{"key":"858_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103669","volume":"75","author":"Y Li","year":"2022","unstructured":"Li Y, Yu T, Han L, Jin L, Jin Y, Quan J (2022) Development of a non-viral gene vector for enhancing gene transfection efficiency. J Drug Deliv Sci Technol 75:103669. https:\/\/doi.org\/10.1016\/j.jddst.2022.103669","journal-title":"J Drug Deliv Sci Technol"},{"key":"858_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/srep14926","volume":"5","author":"K Yin","year":"2015","unstructured":"Yin K et al (2015) A geminivirus-based guide RNA delivery system for CRISPR\/Cas9 mediated plant genome editing. Sci Rep 5:14926. https:\/\/doi.org\/10.1038\/srep14926","journal-title":"Sci Rep"},{"key":"858_CR66","unstructured":"Therapeutic genome editing prospects and challenges | Nature Medicine. Accessed: Aug. 21, 2025. [Online]. Available: https:\/\/www.nature.com\/articles\/nm.3793"},{"issue":"6","key":"858_CR67","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.celrep.2015.07.019","volume":"12","author":"E Zinn","year":"2015","unstructured":"Zinn E et al (2015) In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep 12(6):1056\u20131068. https:\/\/doi.org\/10.1016\/j.celrep.2015.07.019","journal-title":"Cell Rep"},{"key":"858_CR68","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jconrel.2019.02.009","volume":"298","author":"CJ Stephens","year":"2019","unstructured":"Stephens CJ, Lauron EJ, Kashentseva E, Lu ZH, Yokoyama WM, Curiel DT (2019) Long-term correction of hemophilia B using adenoviral delivery of CRISPR\/Cas9. J Control Release 298:128\u2013141. https:\/\/doi.org\/10.1016\/j.jconrel.2019.02.009","journal-title":"J Control Release"},{"issue":"4","key":"858_CR69","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/mt.2015.231","volume":"24","author":"SR Choudhury","year":"2016","unstructured":"Choudhury SR et al (2016) Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector. Mol Ther 24(4):726\u2013735. https:\/\/doi.org\/10.1038\/mt.2015.231","journal-title":"Mol Ther"},{"issue":"1","key":"858_CR70","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu Z, Yang H, Colosi P (2010) Effect of genome size on AAV vector packaging. Mol Ther 18(1):80\u201386. https:\/\/doi.org\/10.1038\/mt.2009.255","journal-title":"Mol Ther"},{"issue":"6","key":"858_CR71","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli C, Soltys S, Rengo G, Rabinowitz JE (2008) Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection. Mol Ther J Am Soc Gene Ther 16(6):1073\u20131080. https:\/\/doi.org\/10.1038\/mt.2008.76","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"2","key":"858_CR72","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.nbd.2004.03.005","volume":"16","author":"M Griffey","year":"2004","unstructured":"Griffey M et al (2004) Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis 16(2):360\u2013369. https:\/\/doi.org\/10.1016\/j.nbd.2004.03.005","journal-title":"Neurobiol Dis"},{"issue":"7","key":"858_CR73","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"S Duque","year":"2009","unstructured":"Duque S et al (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17(7):1187\u20131196. https:\/\/doi.org\/10.1038\/mt.2009.71","journal-title":"Mol Ther"},{"issue":"2","key":"858_CR74","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","volume":"10","author":"C Burger","year":"2004","unstructured":"Burger C et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10(2):302\u2013317. https:\/\/doi.org\/10.1016\/j.ymthe.2004.05.024","journal-title":"Mol Ther"},{"issue":"2","key":"858_CR75","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt RJ et al (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159(2):440\u2013455. https:\/\/doi.org\/10.1016\/j.cell.2014.09.014","journal-title":"Cell"},{"key":"858_CR76","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan KY et al (2017) Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci 20:1172\u20131179. https:\/\/doi.org\/10.1038\/nn.4593","journal-title":"Nat Neurosci"},{"key":"858_CR77","unstructured":"CNS-restricted Transduction and CRISPR\/Cas9-mediated Gene Deletion with an Engineered AAV Vector - PubMed. Accessed: Aug. 21, 2025. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/27434683\/"},{"key":"858_CR78","unstructured":"Engineering adeno-associated viruses for clinical gene therapy | Nature Reviews Genetics. Accessed: Aug. 21, 2025. [Online]. Available: https:\/\/www.nature.com\/articles\/nrg3742"},{"key":"858_CR79","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","volume":"28","author":"A Li","year":"2020","unstructured":"Li A et al (2020) AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9. Mol Ther 28:1432\u20131441. https:\/\/doi.org\/10.1016\/j.ymthe.2020.04.017","journal-title":"Mol Ther"},{"issue":"10","key":"858_CR80","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41551-019-0431-2","volume":"3","author":"AM Moreno","year":"2019","unstructured":"Moreno AM et al (2019) Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. Nat Biomed Eng 3(10):806\u2013816. https:\/\/doi.org\/10.1038\/s41551-019-0431-2","journal-title":"Nat Biomed Eng"},{"issue":"6","key":"858_CR81","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/glia.20795","volume":"57","author":"A Colin","year":"2009","unstructured":"Colin A et al (2009) Engineered lentiviral vector targeting astrocytes in vivo. Glia 57(6):667\u2013679. https:\/\/doi.org\/10.1002\/glia.20795","journal-title":"Glia"},{"issue":"4","key":"858_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18040754","volume":"18","author":"N Kolli","year":"2017","unstructured":"Kolli N, Lu M, Maiti P, Rossignol J, Dunbar GL (2017) CRISPR-Cas9 mediated gene-silencing of the mutant Huntingtin gene in an in vitro model of huntington\u2019s disease. Int J Mol Sci 18(4):754. https:\/\/doi.org\/10.3390\/ijms18040754","journal-title":"Int J Mol Sci"},{"issue":"12","key":"858_CR83","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","volume":"20","author":"N Merienne","year":"2017","unstructured":"Merienne N et al (2017) The self-inactivating KamiCas9 system for the editing of CNS disease genes. Cell Rep 20(12):2980\u20132991. https:\/\/doi.org\/10.1016\/j.celrep.2017.08.075","journal-title":"Cell Rep"},{"key":"858_CR84","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.omtm.2021.02.005","volume":"20","author":"Q Li","year":"2021","unstructured":"Li Q et al (2021) In vivo PCSK9 gene editing using an all-in-one self-cleavage AAV-CRISPR system. Mol Ther 20:652\u2013659. https:\/\/doi.org\/10.1016\/j.omtm.2021.02.005","journal-title":"Mol Ther"},{"issue":"1","key":"858_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12449-2","volume":"10","author":"KS Hanlon","year":"2019","unstructured":"Hanlon KS et al (2019) High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun 10(1):4439. https:\/\/doi.org\/10.1038\/s41467-019-12449-2","journal-title":"Nat Commun"},{"issue":"10","key":"858_CR86","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nmeth.3993","volume":"13","author":"WL Chew","year":"2016","unstructured":"Chew WL et al (2016) A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods 13(10):868\u2013874. https:\/\/doi.org\/10.1038\/nmeth.3993","journal-title":"Nat Methods"},{"issue":"11","key":"858_CR87","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1128\/JVI.00014-10","volume":"84","author":"K Breckpot","year":"2010","unstructured":"Breckpot K et al (2010) HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 84(11):5627\u20135636. https:\/\/doi.org\/10.1128\/JVI.00014-10","journal-title":"J Virol"},{"issue":"7","key":"858_CR88","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/hum.2015.087","volume":"26","author":"D Wang","year":"2015","unstructured":"Wang D et al (2015) Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther 26(7):432\u2013442. https:\/\/doi.org\/10.1089\/hum.2015.087","journal-title":"Hum Gene Ther"},{"key":"858_CR89","unstructured":"A split- Cas9 architecture for inducible genome editing and transcription modulation | Nature Biotechnology. Accessed: Aug. 21, 2025. [Online]. Available: https:\/\/www.nature.com\/articles\/nbt.3149"},{"key":"858_CR90","doi-asserted-by":"publisher","unstructured":"Exploring polyethylenimine- mediated DNA transfection and the proton sponge hypothesis - Akinc \u2013\u20092005 - The Journal of Gene Medicine - Wiley Online Library. Accessed: Aug. 21, 2025. [Online]. Available: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/jgm.696","DOI":"10.1002\/jgm.696"},{"key":"858_CR91","doi-asserted-by":"publisher","unstructured":"Lipid nanoparticle- mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3 | PNAS. Accessed: Aug. 21, 2025. [Online]. Available: https:\/\/www.pnas.org\/doi\/full\/https:\/\/doi.org\/10.1073\/pnas.2020401118","DOI":"10.1073\/pnas.2020401118"},{"key":"858_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2022.119691","volume":"292","author":"Z Khademi","year":"2022","unstructured":"Khademi Z et al (2022) A novel dual-targeting delivery system for specific delivery of CRISPR\/Cas9 using hyaluronic acid, chitosan and AS1411. Carbohydr Polym 292:119691. https:\/\/doi.org\/10.1016\/j.carbpol.2022.119691","journal-title":"Carbohydr Polym"},{"key":"858_CR93","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.biomaterials.2016.11.052","volume":"118","author":"KL Hess","year":"2017","unstructured":"Hess KL, Andorko JI, Tostanoski LH, Jewell CM (2017) Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity. Biomaterials 118:51\u201362. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.11.052","journal-title":"Biomaterials"},{"issue":"19","key":"858_CR94","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1073\/pnas.1712963115","volume":"115","author":"H-X Wang","year":"2018","unstructured":"Wang H-X et al (2018) Nonviral gene editing via CRISPR\/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide. Proc Natl Acad Sci U S A 115(19):4903\u20134908. https:\/\/doi.org\/10.1073\/pnas.1712963115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"858_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901187","volume":"31","author":"L Li","year":"2019","unstructured":"Li L et al (2019) A rationally designed semiconducting polymer brush for NIR-II imaging-guided light-triggered remote control of CRISPR\/Cas9 genome editing. Adv Mater 31(21):1901187. https:\/\/doi.org\/10.1002\/adma.201901187","journal-title":"Adv Mater"},{"issue":"51","key":"858_CR96","doi-asserted-by":"publisher","first-page":"15536","DOI":"10.1073\/pnas.1521670112","volume":"112","author":"KT Gagnon","year":"2015","unstructured":"Gagnon KT, Corey DR (2015) Stepping toward therapeutic CRISPR. Proc Natl Acad Sci U S A 112(51):15536\u201315537. https:\/\/doi.org\/10.1073\/pnas.1521670112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"858_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-019-0452-8","volume":"17","author":"EY Cho","year":"2019","unstructured":"Cho EY et al (2019) Lecithin nano-liposomal particle as a CRISPR\/Cas9 complex delivery system for treating type 2 diabetes. J Nanobiotechnol 17(1):19. https:\/\/doi.org\/10.1186\/s12951-019-0452-8","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"858_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17029-3","volume":"11","author":"T Wei","year":"2020","unstructured":"Wei T, Cheng Q, Min Y-L, Olson EN, Siegwart DJ (2020) Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun 11(1):3232. https:\/\/doi.org\/10.1038\/s41467-020-17029-3","journal-title":"Nat Commun"},{"key":"858_CR99","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jconrel.2020.12.013","volume":"330","author":"Y Suzuki","year":"2021","unstructured":"Suzuki Y et al (2021) Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition. J Control Release 330:61\u201371. https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.013","journal-title":"J Control Release"},{"issue":"11","key":"858_CR100","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1073\/pnas.1520244113","volume":"113","author":"M Wang","year":"2016","unstructured":"Wang M et al (2016) Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A 113(11):2868\u20132873. https:\/\/doi.org\/10.1073\/pnas.1520244113","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"858_CR101","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1021\/acs.accounts.8b00493","volume":"52","author":"J Chang","year":"2019","unstructured":"Chang J et al (2019) Integrating combinatorial lipid nanoparticle and chemically modified protein for intracellular delivery and genome editing. Acc Chem Res 52(3):665\u2013675. https:\/\/doi.org\/10.1021\/acs.accounts.8b00493","journal-title":"Acc Chem Res"},{"issue":"9","key":"858_CR102","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD et al (2018) A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 22(9):2227\u20132235. https:\/\/doi.org\/10.1016\/j.celrep.2018.02.014","journal-title":"Cell Rep"},{"issue":"9","key":"858_CR103","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu Y et al (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31(9):822\u2013826. https:\/\/doi.org\/10.1038\/nbt.2623","journal-title":"Nat Biotechnol"},{"issue":"9","key":"858_CR104","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nbt.2675","volume":"31","author":"P Mali","year":"2013","unstructured":"Mali P et al (2013) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31(9):833\u2013838. https:\/\/doi.org\/10.1038\/nbt.2675","journal-title":"Nat Biotechnol"},{"issue":"2","key":"858_CR105","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG et al (2016) Optimized SgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34(2):184\u2013191. https:\/\/doi.org\/10.1038\/nbt.3437","journal-title":"Nat Biotechnol"},{"issue":"1","key":"858_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1381-1","volume":"19","author":"R Aman","year":"2018","unstructured":"Aman R et al (2018) RNA virus interference via CRISPR\/Cas13a system in plants. Genome Biol 19(1):1. https:\/\/doi.org\/10.1186\/s13059-017-1381-1","journal-title":"Genome Biol"},{"issue":"7","key":"858_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071608","volume":"9","author":"M Naeem","year":"2020","unstructured":"Naeem M, Majeed S, Hoque MZ, Ahmad I (2020) Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. Cells 9(7):1608. https:\/\/doi.org\/10.3390\/cells9071608","journal-title":"Cells"},{"issue":"4","key":"858_CR108","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nmeth.2845","volume":"11","author":"JP Guilinger","year":"2014","unstructured":"Guilinger JP et al (2014) Broad specificity profiling of TALENs results in engineered nucleases with improved DNA cleavage specificity. Nat Methods 11(4):429\u2013435. https:\/\/doi.org\/10.1038\/nmeth.2845","journal-title":"Nat Methods"},{"issue":"5891","key":"858_CR109","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1126\/science.1159689","volume":"321","author":"SJJ Brouns","year":"2008","unstructured":"Brouns SJJ et al (2008) Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321(5891):960\u2013964. https:\/\/doi.org\/10.1126\/science.1159689","journal-title":"Science"},{"issue":"18","key":"858_CR110","doi-asserted-by":"publisher","first-page":"10059","DOI":"10.1093\/nar\/gkad676","volume":"51","author":"J Haldrup","year":"2023","unstructured":"Haldrup J et al (2023) Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR\/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Res 51(18):10059\u201310074. https:\/\/doi.org\/10.1093\/nar\/gkad676","journal-title":"Nucleic Acids Res"},{"key":"858_CR111","unstructured":"Biotec C 2018.03.03.11, Revista Bionatura. Accessed: Aug. 22, 2025. [Online]. Available: http:\/\/revistabionatura.com\/2018.03.03.11.html"},{"key":"858_CR112","unstructured":"Precision Modulation of Neurodegenerative Disease-Related Gene Expression in Human iPSC-Derived Neurons | Scientific Reports. Accessed: Aug. 22, 2025. [Online]. Available: https:\/\/www.nature.com\/articles\/srep28420"},{"issue":"3","key":"858_CR113","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","volume":"8","author":"X Xu","year":"2017","unstructured":"Xu X et al (2017) Reversal of phenotypic abnormalities by CRISPR\/Cas9-mediated gene correction in huntington disease patient-derived induced pluripotent stem cells. Stem Cell Reports 8(3):619\u2013633. https:\/\/doi.org\/10.1016\/j.stemcr.2017.01.022","journal-title":"Stem Cell Reports"},{"issue":"7699","key":"858_CR114","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature26155","volume":"556","author":"JH Hu","year":"2018","unstructured":"Hu JH et al (2018) Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 556(7699):57\u201363. https:\/\/doi.org\/10.1038\/nature26155","journal-title":"Nature"},{"key":"858_CR115","unstructured":"Genome-wide target specificity of CRISPR RNA-guided adenine base editors | Nature Biotechnology. Accessed: Aug. 22, 2025. [Online]. Available: https:\/\/www.nature.com\/articles\/s41587-019-0050-1"},{"issue":"1","key":"858_CR116","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.molp.2019.10.007","volume":"13","author":"W Xu","year":"2020","unstructured":"Xu W et al (2020) Discriminated sgrnas-based surrogate system greatly enhances the screening efficiency of plant base-edited cells. Mol Plant 13(1):169\u2013180. https:\/\/doi.org\/10.1016\/j.molp.2019.10.007","journal-title":"Mol Plant"},{"issue":"3","key":"858_CR117","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nbt.2808","volume":"32","author":"Y Fu","year":"2014","unstructured":"Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32(3):279\u2013284. https:\/\/doi.org\/10.1038\/nbt.2808","journal-title":"Nat Biotechnol"},{"issue":"1","key":"858_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16542-9","volume":"11","author":"JC Rose","year":"2020","unstructured":"Rose JC et al (2020) Suppression of unwanted CRISPR-Cas9 editing by co-administration of catalytically inactivating truncated guide RNAs. Nat Commun 11(1):2697. https:\/\/doi.org\/10.1038\/s41467-020-16542-9","journal-title":"Nat Commun"},{"key":"858_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15790","volume":"8","author":"HA Rees","year":"2017","unstructured":"Rees HA et al (2017) Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat Commun 8:15790. https:\/\/doi.org\/10.1038\/ncomms15790","journal-title":"Nat Commun"},{"issue":"6437","key":"858_CR120","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.aav9973","volume":"364","author":"E Zuo","year":"2019","unstructured":"Zuo E et al (2019) Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science 364(6437):289\u2013292. https:\/\/doi.org\/10.1126\/science.aav9973","journal-title":"Science"},{"key":"858_CR121","unstructured":"Cytosine but not adenine, base editors induce genome-wide off-target mutations in rice - PubMed. Accessed: Aug. 22, 2025. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/30819931\/"},{"key":"858_CR122","doi-asserted-by":"publisher","unstructured":"Karik\u00f3 K, Bhuyan P, Capodici J, Weissman D (2004) Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol Baltim Md (1950), 172(11):6545\u20136549. https:\/\/doi.org\/10.4049\/jimmunol.172.11.6545","DOI":"10.4049\/jimmunol.172.11.6545"},{"key":"858_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-8-126","volume":"8","author":"SL Butland","year":"2007","unstructured":"Butland SL et al (2007) CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics 8:126. https:\/\/doi.org\/10.1186\/1471-2164-8-126","journal-title":"BMC Genomics"},{"key":"858_CR124","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","volume":"10","author":"F Uddin","year":"2020","unstructured":"Uddin F, Rudin CM, Sen T (2020) Therapy: Applications, Limitations, and implications for the future. Front Oncol 10:1387. https:\/\/doi.org\/10.3389\/fonc.2020.01387","journal-title":"Front Oncol"},{"issue":"1","key":"858_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00609-1","volume":"8","author":"D Cesana","year":"2017","unstructured":"Cesana D et al (2017) HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. Nat Commun 8(1):498. https:\/\/doi.org\/10.1038\/s41467-017-00609-1","journal-title":"Nat Commun"},{"issue":"7709","key":"858_CR126","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA et al (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558(7709):307\u2013312. https:\/\/doi.org\/10.1038\/s41586-018-0178-z","journal-title":"Nature"},{"issue":"12","key":"858_CR127","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/JOM.0000000000000879","volume":"58","author":"R Schlimgen","year":"2016","unstructured":"Schlimgen R et al (2016) Risks associated with lentiviral vector exposures and prevention strategies. J Occup Environ Med 58(12):1159\u20131166. https:\/\/doi.org\/10.1097\/JOM.0000000000000879","journal-title":"J Occup Environ Med"},{"issue":"7580","key":"858_CR128","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1038\/528S17a","volume":"528","author":"W Tauxe","year":"2015","unstructured":"Tauxe W (2015) Genome editing: 4 big questions. Nature 528(7580):S17. https:\/\/doi.org\/10.1038\/528S17a","journal-title":"Nature"},{"issue":"2","key":"858_CR129","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1534\/genetics.110.120717","volume":"186","author":"M Christian","year":"2010","unstructured":"Christian M et al (2010) Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186(2):757\u2013761. https:\/\/doi.org\/10.1534\/genetics.110.120717","journal-title":"Genetics"},{"key":"858_CR130","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver BP et al (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529:490\u2013495. https:\/\/doi.org\/10.1038\/nature16526","journal-title":"Nature"},{"issue":"4","key":"858_CR131","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.molcel.2013.05.001","volume":"50","author":"Y Zhang","year":"2013","unstructured":"Zhang Y et al (2013) Processing-independent CRISPR RNAs limit natural transformation in Neisseria meningitidis. Mol Cell 50(4):488\u2013503. https:\/\/doi.org\/10.1016\/j.molcel.2013.05.001","journal-title":"Mol Cell"},{"issue":"11","key":"858_CR132","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nmeth.2681","volume":"10","author":"KM Esvelt","year":"2013","unstructured":"Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM (2013) Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods 10(11):1116\u20131121. https:\/\/doi.org\/10.1038\/nmeth.2681","journal-title":"Nat Methods"},{"issue":"7546","key":"858_CR133","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran FA et al (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 520(7546):186\u2013191. https:\/\/doi.org\/10.1038\/nature14299","journal-title":"Nature"},{"issue":"8","key":"858_CR134","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nbt.3609","volume":"34","author":"D Kim","year":"2016","unstructured":"Kim D, Kim J, Hur JK, Been KW, Yoon S-H, Kim J-S (2016) Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat Biotechnol 34(8):863\u2013868. https:\/\/doi.org\/10.1038\/nbt.3609","journal-title":"Nat Biotechnol"},{"issue":"3","key":"858_CR135","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","volume":"163","author":"B Zetsche","year":"2015","unstructured":"Zetsche B et al (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163(3):759\u2013771. https:\/\/doi.org\/10.1016\/j.cell.2015.09.038","journal-title":"Cell"},{"issue":"4","key":"858_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007308","volume":"14","author":"Y Choi","year":"2018","unstructured":"Choi Y, Chan AP, Kirkness E, Telenti A, Schork NJ (2018) Comparison of phasing strategies for whole human genomes. PLoS Genet 14(4):e1007308. https:\/\/doi.org\/10.1371\/journal.pgen.1007308","journal-title":"PLoS Genet"},{"issue":"3","key":"858_CR137","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ajhg.2012.01.005","volume":"90","author":"J-M Lee","year":"2012","unstructured":"Lee J-M et al (2012) Common SNP-based haplotype analysis of the 4p16.3 huntington disease gene region. Am J Hum Genet 90(3):434\u2013444. https:\/\/doi.org\/10.1016\/j.ajhg.2012.01.005","journal-title":"Am J Hum Genet"},{"issue":"11","key":"858_CR138","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/mt.2015.128","volume":"23","author":"C Kay","year":"2015","unstructured":"Kay C et al (2015) Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European ancestry. Mol Ther 23(11):1759\u20131771. https:\/\/doi.org\/10.1038\/mt.2015.128","journal-title":"Mol Ther"},{"issue":"9","key":"858_CR139","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL et al (2009) Five SiRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr Biol 19(9):774\u2013778. https:\/\/doi.org\/10.1016\/j.cub.2009.03.030","journal-title":"Curr Biol"},{"issue":"8","key":"858_CR140","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/nar\/gkz093","volume":"47","author":"B Lu","year":"2019","unstructured":"Lu B et al (2019) Delivering sacas9 mrna by lentivirus-like bionanoparticles for transient expression and efficient genome editing. Nucleic Acids Res 47(8):e44. https:\/\/doi.org\/10.1093\/nar\/gkz093","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"858_CR141","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota S et al (2022) Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185(2):250-265.e16. https:\/\/doi.org\/10.1016\/j.cell.2021.12.021","journal-title":"Cell"},{"issue":"1","key":"858_CR142","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.tibtech.2016.06.008","volume":"35","author":"G-H Chuai","year":"2017","unstructured":"Chuai G-H, Wang Q-L, Liu Q (2017) In silico meets in vivo: towards computational CRISPR-based sgrna design. Trends Biotechnol 35(1):12\u201321. https:\/\/doi.org\/10.1016\/j.tibtech.2016.06.008","journal-title":"Trends Biotechnol"},{"issue":"1","key":"858_CR143","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","volume":"26","author":"KH Morelli","year":"2023","unstructured":"Morelli KH et al (2023) An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in huntington\u2019s disease models. Nat Neurosci 26(1):27\u201338. https:\/\/doi.org\/10.1038\/s41593-022-01207-1","journal-title":"Nat Neurosci"},{"key":"858_CR144","doi-asserted-by":"publisher","unstructured":"Choi DE et al (2023) Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington\u2019s disease, BioRxiv Prepr. Serv. Biol., p. 2023.04.28.538700, Apr. https:\/\/doi.org\/10.1101\/2023.04.28.538700","DOI":"10.1101\/2023.04.28.538700"},{"issue":"7675","key":"858_CR145","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","volume":"550","author":"OO Abudayyeh","year":"2017","unstructured":"Abudayyeh OO et al (2017) RNA targeting with CRISPR-Cas13. Nature 550(7675):280\u2013284. https:\/\/doi.org\/10.1038\/nature24049","journal-title":"Nature"},{"key":"858_CR146","doi-asserted-by":"publisher","unstructured":"Zhang C et al (2018) Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-Cas13d. Cell 175(1):212\u2013223. https:\/\/doi.org\/10.1016\/j.cell.2018.09.001. .e17","DOI":"10.1016\/j.cell.2018.09.001"},{"key":"858_CR147","unstructured":"A thermostable Cas9 with increased lifetime in human plasma | Nature Communications. Accessed: Aug. 22, 2025. [Online]. Available: https:\/\/www.nature.com\/articles\/s41467-017-01408-4"},{"issue":"3","key":"858_CR148","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1101\/gr.231936.117","volume":"28","author":"S Kim","year":"2018","unstructured":"Kim S et al (2018) CRISPR RNAs trigger innate immune responses in human cells. Genome Res 28(3):367\u2013373. https:\/\/doi.org\/10.1101\/gr.231936.117","journal-title":"Genome Res"},{"issue":"1","key":"858_CR149","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","volume":"181","author":"D Wang","year":"2020","unstructured":"Wang D, Zhang F, Gao G (2020) CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181(1):136\u2013150. https:\/\/doi.org\/10.1016\/j.cell.2020.03.023","journal-title":"Cell"},{"issue":"1","key":"858_CR150","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","volume":"26","author":"M Bravo-Hernandez","year":"2020","unstructured":"Bravo-Hernandez M et al (2020) Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med 26(1):118\u2013130. https:\/\/doi.org\/10.1038\/s41591-019-0674-1","journal-title":"Nat Med"},{"key":"858_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.29","volume":"2","author":"DJ Hui","year":"2015","unstructured":"Hui DJ et al (2015) AAV capsid CD8\u2009+\u2009t-cell epitopes are highly conserved across AAV serotypes. Mol Ther 2:15029. https:\/\/doi.org\/10.1038\/mtm.2015.29","journal-title":"Mol Ther"},{"issue":"4","key":"858_CR152","doi-asserted-by":"publisher","first-page":"ENEURO.0188-21.","DOI":"10.1523\/ENEURO.0188-21.2021","volume":"8","author":"NVN Carullo","year":"2021","unstructured":"Carullo NVN, Hinds JE, Revanna JS, Tuscher JJ, Bauman AJ, Day JJ (2021) A Cre-dependent CRISPR\/dCas9 system for gene expression regulation in neurons. eNeuro 8(4):ENEURO.0188-21.2021. https:\/\/doi.org\/10.1523\/ENEURO.0188-21.2021","journal-title":"eNeuro"},{"issue":"2","key":"858_CR153","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT et al (2019) Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 25(2):249\u2013254. https:\/\/doi.org\/10.1038\/s41591-018-0326-x","journal-title":"Nat Med"},{"issue":"2","key":"858_CR154","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","volume":"25","author":"DL Wagner","year":"2019","unstructured":"Wagner DL et al (2019) High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med 25(2):242\u2013248. https:\/\/doi.org\/10.1038\/s41591-018-0204-6","journal-title":"Nat Med"},{"key":"858_CR155","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","volume":"10","author":"VL Simhadri","year":"2018","unstructured":"Simhadri VL, McGill J, McMahon S, Wang J, Jiang H, Sauna ZE (2018) Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol Ther 10:105\u2013112. https:\/\/doi.org\/10.1016\/j.omtm.2018.06.006","journal-title":"Mol Ther"},{"key":"858_CR156","doi-asserted-by":"publisher","unstructured":"R. E (2016) Ethical issues in genome editing using Crispr\/Cas9 system. J Clin Res Bioeth, 07, 02.\u00a0https:\/\/doi.org\/10.4172\/2155-9627.1000266","DOI":"10.4172\/2155-9627.1000266"},{"issue":"1","key":"858_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09693-x","volume":"10","author":"SR Ferdosi","year":"2019","unstructured":"Ferdosi SR et al (2019) Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat Commun 10(1):1842. https:\/\/doi.org\/10.1038\/s41467-019-09693-x","journal-title":"Nat Commun"},{"issue":"7","key":"858_CR158","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s41591-022-01848-6","volume":"28","author":"X-ZE Tang","year":"2022","unstructured":"Tang X-ZE, Tan SX, Hoon S, Yeo GW (2022) Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans. Nat Med 28(7):1372\u20131376. https:\/\/doi.org\/10.1038\/s41591-022-01848-6","journal-title":"Nat Med"},{"key":"858_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29844-x","volume":"13","author":"MA Toral","year":"2022","unstructured":"Toral MA et al (2022) Author correction: investigation of Cas9 antibodies in the human eye. Nat Commun 13:2109. https:\/\/doi.org\/10.1038\/s41467-022-29844-x","journal-title":"Nat Commun"},{"key":"858_CR160","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","volume":"12","author":"S Vaidyanathan","year":"2018","unstructured":"Vaidyanathan S et al (2018) Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol Ther Nucleic Acids 12:530\u2013542. https:\/\/doi.org\/10.1016\/j.omtn.2018.06.010","journal-title":"Mol Ther Nucleic Acids"},{"key":"858_CR161","unstructured":"Human Gene Therapy Products Incorporating Human Genome Editing Draft Guidance for Industry; Availability, Federal Register. Accessed: Aug. 23, 2025. [Online]. Available: https:\/\/www.federalregister.gov\/documents\/2022\/03\/16\/2022-05538\/human-gene-therapy-products-incorporating-human-genome-editing-draft-guidance-for-industry"},{"issue":"2","key":"858_CR162","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ajhg.2017.06.012","volume":"101","author":"KE Ormond","year":"2017","unstructured":"Ormond KE et al (2017) Human germline genome editing. Am J Hum Genet 101(2):167\u2013176. https:\/\/doi.org\/10.1016\/j.ajhg.2017.06.012","journal-title":"Am J Hum Genet"},{"issue":"5","key":"858_CR163","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13238-015-0153-5","volume":"6","author":"P Liang","year":"2015","unstructured":"Liang P et al (2015) CRISPR\/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5):363\u2013372. https:\/\/doi.org\/10.1007\/s13238-015-0153-5","journal-title":"Protein Cell"},{"issue":"1","key":"858_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-021-00317-4","volume":"15","author":"S Mezinska","year":"2021","unstructured":"Mezinska S, Gallagher L, Verbrugge M, Bunnik EM (2021) Ethical issues in genomics research on neurodevelopmental disorders: a critical interpretive review. Hum Genomics 15(1):16. https:\/\/doi.org\/10.1186\/s40246-021-00317-4","journal-title":"Hum Genomics"},{"key":"858_CR165","unstructured":"Concerning RNA-guided gene drives for the alteration of wild populations - PubMed. Accessed: Aug. 23, 2025. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/25035423\/"},{"key":"858_CR166","unstructured":"Long-term maintenance of human induced pluripotent stem cells by automated cell culture system | Scientific Reports. Accessed: Aug. 23, 2025. [Online]. Available: https:\/\/www.nature.com\/articles\/srep16647"},{"issue":"3","key":"858_CR167","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.stem.2020.08.013","volume":"27","author":"A Bhaduri","year":"2020","unstructured":"Bhaduri A, Andrews MG, Kriegstein AR, Nowakowski TJ (2020) Are organoids ready for prime time? Cell Stem Cell 27(3):361\u2013365. https:\/\/doi.org\/10.1016\/j.stem.2020.08.013","journal-title":"Cell Stem Cell"},{"key":"858_CR168","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/612823","volume":"2014","author":"Z Hu","year":"2014","unstructured":"Hu Z et al (2014) Disruption of HPV16-E7 by CRISPR\/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. BioMed Res Int 2014:612823. https:\/\/doi.org\/10.1155\/2014\/612823","journal-title":"BioMed Res Int"},{"issue":"7","key":"858_CR169","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","volume":"24","author":"RJ Ihry","year":"2018","unstructured":"Ihry RJ et al (2018) P53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med 24(7):939\u2013946. https:\/\/doi.org\/10.1038\/s41591-018-0050-6","journal-title":"Nat Med"},{"key":"858_CR170","doi-asserted-by":"publisher","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A (2022) Current and possible future therapeutic options for Huntington\u2019s disease. J Cent Nerv Syst Dis 14:11795735221092517. https:\/\/doi.org\/10.1177\/11795735221092517","journal-title":"J Cent Nerv Syst Dis"},{"issue":"2","key":"858_CR171","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","volume":"29","author":"G Sharma","year":"2021","unstructured":"Sharma G, Sharma AR, Bhattacharya M, Lee S-S, Chakraborty C (2021) CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol Ther 29(2):571\u2013586. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.028","journal-title":"Mol Ther"},{"key":"858_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1364742","volume":"15","author":"M-L Zhang","year":"2024","unstructured":"Zhang M-L, Li H-B, Jin Y (2024) Application and perspective of CRISPR\/Cas9 genome editing technology in human diseases modeling and gene therapy. Front Genet 15:1364742. https:\/\/doi.org\/10.3389\/fgene.2024.1364742","journal-title":"Front Genet"},{"issue":"10","key":"858_CR173","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/14737175.2019.1631161","volume":"19","author":"H Bashir","year":"2019","unstructured":"Bashir H (2019) Emerging therapies in Huntington\u2019s disease. Expert Rev Neurother 19(10):983\u2013995. https:\/\/doi.org\/10.1080\/14737175.2019.1631161","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"858_CR174","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s12264-022-00880-3","volume":"38","author":"Y Qin","year":"2022","unstructured":"Qin Y, Li S, Li X-J, Yang S (2022) CRISPR-based genome-editing tools for Huntington\u2019s disease research and therapy. Neurosci Bull 38(11):1397\u20131408. https:\/\/doi.org\/10.1007\/s12264-022-00880-3","journal-title":"Neurosci Bull"},{"key":"858_CR175","unstructured":"Therapeutic Update on Huntington\u2019s Disease Symptomatic Treatments and Emerging Disease-Modifying Therapies - PubMed. Accessed: Aug. 23, 2025. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/32705582\/"},{"key":"858_CR176","unstructured":"H.- www.ushealthconnect.com Clinical Trials for Huntington Disease - PracticalNeurology. Accessed: Aug. 23, 2025. [Online]. Available: https:\/\/practicalneurology.com\/diseases-diagnoses\/movement-disorders\/clinical-trials-for-huntington-disease\/31681\/"},{"issue":"6","key":"858_CR177","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"FA Ran","year":"2013","unstructured":"Ran FA et al (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154(6):1380\u20131389. https:\/\/doi.org\/10.1016\/j.cell.2013.08.021","journal-title":"Cell"},{"key":"858_CR178","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jbiotec.2015.04.024","volume":"208","author":"X Liang","year":"2015","unstructured":"Liang X (2015) Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol 208:44\u201353. https:\/\/doi.org\/10.1016\/j.jbiotec.2015.04.024","journal-title":"J Biotechnol"},{"issue":"2","key":"858_CR179","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/crispr.2017.0024","volume":"1","author":"C Brokowski","year":"2018","unstructured":"Brokowski C (2018) Do CRISPR germline ethics statements cut it? CRISPR J 1(2):115\u2013125. https:\/\/doi.org\/10.1089\/crispr.2017.0024","journal-title":"CRISPR J"},{"issue":"2","key":"858_CR180","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/jlb\/lsw016","volume":"3","author":"S Polcz","year":"2016","unstructured":"Polcz S, Lewis A (2016) Crispr-Cas9 and the non-germline non-controversy. J Law Biosci 3(2):413\u2013425. https:\/\/doi.org\/10.1093\/jlb\/lsw016","journal-title":"J Law Biosci"},{"issue":"4","key":"858_CR181","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12687-017-0316-6","volume":"8","author":"AR Bentley","year":"2017","unstructured":"Bentley AR, Callier S, Rotimi CN (2017) Diversity and inclusion in genomic research: why the uneven progress? J Community Genet 8(4):255\u2013266. https:\/\/doi.org\/10.1007\/s12687-017-0316-6","journal-title":"J Community Genet"}],"container-title":["Neurogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-025-00858-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10048-025-00858-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-025-00858-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T04:04:39Z","timestamp":1769400279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10048-025-00858-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":181,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["858"],"URL":"https:\/\/doi.org\/10.1007\/s10048-025-00858-z","relation":{},"ISSN":["1364-6753"],"issn-type":[{"value":"1364-6753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}